BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 19857148)

  • 1. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
    Strasfeld L; Weinstock DM
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.
    Kontoyiannis DP
    Bone Marrow Transplant; 2011 Feb; 46(2):165-73. PubMed ID: 21042306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.
    Kontoyiannis DP; Marr KA; Park BJ; Alexander BD; Anaissie EJ; Walsh TJ; Ito J; Andes DR; Baddley JW; Brown JM; Brumble LM; Freifeld AG; Hadley S; Herwaldt LA; Kauffman CA; Knapp K; Lyon GM; Morrison VA; Papanicolaou G; Patterson TF; Perl TM; Schuster MG; Walker R; Wannemuehler KA; Wingard JR; Chiller TM; Pappas PG
    Clin Infect Dis; 2010 Apr; 50(8):1091-100. PubMed ID: 20218877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
    Michallet M; Ito JI
    J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
    Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
    Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic SCT in patients with a history of invasive fungal infection.
    Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
    Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.
    Hamza NS; Ghannoum MA; Lazarus HM
    Bone Marrow Transplant; 2004 Sep; 34(5):377-89. PubMed ID: 15247928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic antifungal agents used after lung transplantation.
    Marino E; Gallagher JC
    Ann Pharmacother; 2010 Mar; 44(3):546-56. PubMed ID: 20179260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation.
    Camps IR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S119-23. PubMed ID: 19013335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.